Depression Clinical Trial
Official title:
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data about mechanism of action.
Up to one half of older patients with major depression develop Late-Life Treatment Resistant
Depression (LL-TRD). Consequences of LL-TRD include suicide, worsened medical conditions,
increased caregiver burden, and higher all-cause mortality. The development and testing of
novel-mechanism pharmacotherapies is a public health priority embraced by National Institute
of Mental Health (NIMH). Among the neuropeptidergic transmitters, opioids are known to
modulate mood, and this system is often altered in patients with major depression. Targeting
the opiate system in LL-TRD may positively modulate a system in which there is age-associated
imbalance between circulating opiates and the density and binding affinity of mu and kappa
opiate receptors. Buprenorphine (BPN) is an antagonist at the kappa opiate receptor and a
partial agonist at the mu opiate receptor. Either, or both, of these pharmacodynamic actions
may underlie its putative antidepressant effects. Our research group has open pilot data from
15 older adults with prospectively demonstrated treatment resistance to venlafaxine who were
exposed to low-dose BPN, suggesting a clinically meaningful antidepressant effect. In
addition, since BPN: 1) is available in sublingual formulation and 2) has a favorable safety
and pharmacokinetic profile, it is an attractive candidate to re-purpose as a molecule for
LL-TRD. Thus, the overarching aims of this project are to examine the feasibility, safety,
tolerability and clinical effect of low-dose BPN as a novel treatment for LL-TRD and to
develop preliminary data about mechanism of action (MOA).
The overarching aims are to examine the feasibility, safety, and tolerability of
buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression
(LL-TRD). This also involves using translational tools of modern neurobiology (fMRI) to
rapidly obtain proof-of-concept support for further clinical development. Formal dosing
schedules in the use of buprenorphine have yet to be thoroughly established. This study hopes
to determine optimal dosing strategies to improve acceptability.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |